Congrats to the @myESMO #ESMO26 #BestPoster award winner for the #BiliaryTumours track
🩸ctDNA aberrant methylation for early assessment of response
🔮Academic randomised trial ongoing, with biliary cohort being coming soon
👏🏻Congrats to the team from Denmark
#ESMOAmbassadors
48 浏览 · 2 赞 · 0 转发 · 1 回复
Calderasib monotherapy in various KRAS G12C–mutated advanced solid tumors: Results from the phase 1 KANDLELIT-001 study
https://esmocongress.esmo.orgKrascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.orgFirst-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.org- Angela Lamarca@DrAngelaLamarca
And in second place…. @tisseranatalia_ She is evaluating patterns associated with very early relapse in #BiliaryMalignancies KRAS seems to be involved Very interesting hypothesis that she is developing further @myESMO #ESMO26 #ESMOAmbassadors
来源：Angela Lamarca · x.com